206 related articles for article (PubMed ID: 29084059)
1. INSL3 Expression in Leydig Cell Hyperplasia and Leydig Cell Tumors.
Lakis NS; Lombardo KA; Mangray S; Netto GJ; Salles D; Matoso A
Appl Immunohistochem Mol Morphol; 2019 Mar; 27(3):203-209. PubMed ID: 29084059
[TBL] [Abstract][Full Text] [Related]
2. The novel hormone INSL3 is expressed in human testicular Leydig cell tumors: a clinical and immunohistochemical study.
Rossato M; Tavolini IM; Calcagno A; Gardiman M; Dal Moro F; Artibani W
Urol Oncol; 2011; 29(1):33-7. PubMed ID: 19110449
[TBL] [Abstract][Full Text] [Related]
3. Expression patterns of DLK1 and INSL3 identify stages of Leydig cell differentiation during normal development and in testicular pathologies, including testicular cancer and Klinefelter syndrome.
Lottrup G; Nielsen JE; Maroun LL; Møller LM; Yassin M; Leffers H; Skakkebæk NE; Rajpert-De Meyts E
Hum Reprod; 2014 Aug; 29(8):1637-50. PubMed ID: 24908673
[TBL] [Abstract][Full Text] [Related]
4. Abundance of DLK1, differential expression of CYP11B1, CYP21A2 and MC2R, and lack of INSL3 distinguish testicular adrenal rest tumours from Leydig cell tumours.
Lottrup G; Nielsen JE; Skakkebæk NE; Juul A; Rajpert-De Meyts E
Eur J Endocrinol; 2015 Apr; 172(4):491-9. PubMed ID: 25609776
[TBL] [Abstract][Full Text] [Related]
5. Leydig cell hyperplasia in children: Case series and review.
Mennie N; King SK; Marulaiah M; Ferguson P; Heloury Y; Kimber C
J Pediatr Urol; 2017 Apr; 13(2):158-163. PubMed ID: 28238607
[TBL] [Abstract][Full Text] [Related]
6. Calretinin: a valuable marker of normal and neoplastic Leydig cells of the testis.
Augusto D; Leteurtre E; De La Taille A; Gosselin B; Leroy X
Appl Immunohistochem Mol Morphol; 2002 Jun; 10(2):159-62. PubMed ID: 12051635
[TBL] [Abstract][Full Text] [Related]
7. Leydig cell tumors of the testis with unusual features: adipose differentiation, calcification with ossification, and spindle-shaped tumor cells.
Ulbright TM; Srigley JR; Hatzianastassiou DK; Young RH
Am J Surg Pathol; 2002 Nov; 26(11):1424-33. PubMed ID: 12409718
[TBL] [Abstract][Full Text] [Related]
8. Comparative molecular analysis of testicular Leydig cell tumors demonstrates distinct subsets of neoplasms with aggressive histopathologic features.
Rizzo NM; Sholl LM; Idrees MT; Cheville JC; Gupta S; Cornejo KM; Miyamoto H; Hirsch MS; Collins K; Acosta AM
Mod Pathol; 2021 Oct; 34(10):1935-1946. PubMed ID: 34103665
[TBL] [Abstract][Full Text] [Related]
9. Utility of immunostaining for S-100 protein subunits in gonadal sex cord-stromal tumors, with emphasis on the large-cell calcifying Sertoli cell tumor of the testis.
Tanaka Y; Carney JA; Ijiri R; Kato K; Miyake T; Nakatani Y; Misugi K
Hum Pathol; 2002 Mar; 33(3):285-9. PubMed ID: 11979368
[TBL] [Abstract][Full Text] [Related]
10. Steroidogenic acute regulatory protein is a useful marker for Leydig cells and sex-cord stromal tumors.
Dong L; Wang H; Su Z; Niu S; Wang R; Wu L; Chen G
Appl Immunohistochem Mol Morphol; 2011 May; 19(3):226-32. PubMed ID: 21217523
[TBL] [Abstract][Full Text] [Related]
11. Rodent Leydig cell tumorigenesis: a review of the physiology, pathology, mechanisms, and relevance to humans.
Cook JC; Klinefelter GR; Hardisty JF; Sharpe RM; Foster PM
Crit Rev Toxicol; 1999 Mar; 29(2):169-261. PubMed ID: 10213111
[TBL] [Abstract][Full Text] [Related]
12. Inhibin-alpha CD99, HEA125, PLAP, and chromogranin immunoreactivity in testicular neoplasms and the androgen insensitivity syndrome.
Kommoss F; Oliva E; Bittinger F; Kirkpatrick CJ; Amin MB; Bhan AK; Young RH; Scully RE
Hum Pathol; 2000 Sep; 31(9):1055-61. PubMed ID: 11014571
[TBL] [Abstract][Full Text] [Related]
13. Non-tumoural parenchyma in Leydig cell tumours: pathogenetic considerations.
Cajaiba MM; Reyes-Múgica M; Rios JC; Nistal M
Int J Androl; 2008 Jun; 31(3):331-6. PubMed ID: 17573846
[TBL] [Abstract][Full Text] [Related]
14. Origin and evolution of somatic cell testicular tumours in transgenic mice.
Quintana S; Venara M; Rey R; di Clemente N; Chemes HE
J Pathol; 2010 Aug; 221(4):443-51. PubMed ID: 20593483
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical evaluation of GATA-4 in canine testicular tumors.
Ramos-Vara JA; Miller MA
Vet Pathol; 2009 Sep; 46(5):893-6. PubMed ID: 19429994
[TBL] [Abstract][Full Text] [Related]
16. Switch of cadherin expression as a diagnostic tool for Leydig cell tumours.
Bremmer F; Schweyer S; Martin-Ortega M; Hammerlein B; Strauss A; Radzun HJ; Behnes CL
APMIS; 2013 Oct; 121(10):976-81. PubMed ID: 23398382
[TBL] [Abstract][Full Text] [Related]
17. Histamine H4 receptor as a novel therapeutic target for the treatment of Leydig-cell tumours in prepubertal boys.
Abiuso AMB; Varela ML; Haro Durand L; Besio Moreno M; Marcos A; Ponzio R; Rivarola MA; Belgorosky A; Pignataro OP; Berensztein E; Mondillo C
Eur J Cancer; 2018 Mar; 91():125-135. PubMed ID: 29367056
[TBL] [Abstract][Full Text] [Related]
18. Expression analyses of insulin-like peptide 3, RXFP2, LH receptor, and 3β-hydroxysteroid dehydrogenase in testes of normal and cryptorchid dogs.
Hannan MA; Kawate N; Kubo Y; Pathirana IN; Büllesbach EE; Hatoya S; Inaba T; Takahashi M; Tamada H
Theriogenology; 2015 Oct; 84(7):1176-84. PubMed ID: 26220663
[TBL] [Abstract][Full Text] [Related]
19. Human testicular insulin-like factor 3: in relation to development, reproductive hormones and andrological disorders.
Bay K; Andersson AM
Int J Androl; 2011 Apr; 34(2):97-109. PubMed ID: 20550598
[TBL] [Abstract][Full Text] [Related]
20. Leydig cell tumorigenesis - implication of G-protein coupled membrane estrogen receptor, peroxisome proliferator-activated receptor and xenoestrogen exposure. In vivo and in vitro appraisal.
Gorowska-Wojtowicz E; Duliban M; Kudrycka M; Dutka P; Pawlicki P; Milon A; Zarzycka M; Placha W; Kotula-Balak M; Ptak A; Wolski JK; Bilinska B
Tissue Cell; 2019 Dec; 61():51-60. PubMed ID: 31759407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
